APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies

NCT03537482 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Hematologic Malignancies

Interventions

DRUG: APG-2575

Sponsor

Ascentage Pharma Group Inc.